Control Bionics Limited (ASX:CBL)
Australia · Delayed Price · Currency is AUD 0.0380
+0.0010 (2.70%)
Sep 18, 2025, 12:00 PM AEST
Control Bionics Revenue
In the fiscal year ending June 30, 2025, Control Bionics had annual revenue of 6.14M AUD with 14.84% growth. Control Bionics had revenue of 3.25M in the half year ending June 30, 2025, with 18.41% growth.
Revenue
6.14M
Revenue Growth
+14.84%
P/S Ratio
1.88
Revenue / Employee
n/a
Employees
n/a
Market Cap
11.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 6.14M | 794.13K | 14.84% |
| Jun 30, 2024 | 5.35M | -291.61K | -5.17% |
| Jun 30, 2023 | 5.64M | 1.14M | 25.33% |
| Jun 30, 2022 | 4.50M | 413.43K | 10.11% |
| Jun 30, 2021 | 4.09M | 886.39K | 27.68% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Pro Medicus | 212.98M |
| Cochlear | 2.34B |
| Sonic Healthcare | 9.65B |
| Ramsay Health Care | 17.79B |
| Ansell | 3.06B |
| Telix Pharmaceuticals | 1.01B |
| Mesoblast | 26.23M |